Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07113691 · ClinicalTrials.gov registry record · Phase 1
Iadademstat + SBRT With Atezo in ES-SCLC
A Phase 1 study of Extensive Stage Small Cell Lung Cancer (ES-SCLC), sponsored by Yale University.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT07113691 is a Phase 1 study of Extensive Stage Small Cell Lung Cancer (ES-SCLC) that is actively recruiting participants, run by Yale University. The registered enrollment target is 15 participants, below the 315-participant average among 3 other Extensive Stage Small Cell Lung Cancer (ES-SCLC) trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07113691, a Phase 1 study of Extensive Stage Small Cell Lung Cancer (ES-SCLC), is actively recruiting participants, sponsored by Yale University.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a phase 1b dose escalation, open-label, non-randomized study of participants with residual, progressive or recurrent ES-SCLC who previously received platinum-based chemotherapy with or without immune checkpoint inhibitor therapy; participants who have achieved only stable disease at the completion of initial platinum-based treatment are eligible for enrollment.
Conditions Studied
Interventions
- DRUG Atezolizumab
- DRUG Iadademstat
- RADIATION SBRT
Study Locations (1)
Connecticut
- Yale University - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2026-01-20 |
| Est. Completion | 2030-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07113691
The ClinicalTrials.gov registry entry for NCT07113691 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 315-participant average among 3 other Extensive Stage Small Cell Lung Cancer (ES-SCLC) trials with a reported enrollment target (95% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Extensive Stage Small Cell Lung Cancer (ES-SCLC) appearing as the primary indexed condition, and to 3 interventions - of which Atezolizumab is the first listed.
NCT07113691 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT07113691 about?
NCT07113691 is a clinical study titled "Iadademstat + SBRT With Atezo in ES-SCLC". This is a phase 1b dose escalation, open-label, non-randomized study of participants with residual, progressive or recurrent ES-SCLC who previously received platinum-based chemotherapy with or without immune checkpoint inhibitor therapy; participants who have achieved only stable disease at the comp...
What is the current status of trial NCT07113691?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2026-01-20. Estimated completion is 2030-01.
What conditions does trial NCT07113691 study?
This clinical trial studies the following conditions: Extensive Stage Small Cell Lung Cancer (ES-SCLC).
What interventions are being tested in trial NCT07113691?
The interventions under investigation include: Atezolizumab (DRUG), Iadademstat (DRUG), SBRT (RADIATION).
Who is sponsoring clinical trial NCT07113691?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07113691 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
SG and Immunotherapy as Maintenance Therapy for Extensive-stage Small-cell Lung Cancer
RECRUITING · Phase 2
-
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.